Notify me when Camber Capital Management LP files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q2 2025 | 23 | $717,903,750 | +$134,622,500 | -$916,277,370 | -$781,654,870 | ZBH, BAX, HUM, CVS, GMED | 13F-HR | 14 Aug 2025, 16:11 |
| Q1 2025 | 28 | $1,602,640,620 | +$212,396,350 | -$1,150,178,850 | -$937,782,500 | ZBH, BAX, HUM, CVS, GMED | 13F-HR | 15 May 2025, 16:17 |
| Q4 2024 | 36 | $2,556,621,000 | +$599,586,096 | -$393,417,205 | +$206,168,891 | MDT, VTRS, ZBH, HUM, PTCT | 13F-HR | 14 Feb 2025, 08:58 |
| Q3 2024 | 32 | $2,574,870,000 | +$458,652,870 | -$628,206,284 | -$169,553,414 | ZBH, MDT, BAX, VTRS, GMED | 13F-HR | 14 Nov 2024, 09:41 |
| Q2 2024 | 35 | $2,591,140,000 | +$479,479,586 | -$608,264,758 | -$128,785,172 | ZBH, BAX, MDT, UHS, GMED | 13F-HR | 14 Aug 2024, 09:28 |
| Q1 2024 | 34 | $2,860,289,000 | +$313,660,318 | -$607,713,776 | -$294,053,458 | ZBH, UHS, BAX, THC, VTRS | 13F-HR | 15 May 2024, 08:48 |
| Q4 2023 | 36 | $2,860,436,000 | +$444,812,851 | -$623,341,537 | -$178,528,686 | UHS, THC, ZBH, VTRS, BAX | 13F-HR | 14 Feb 2024, 08:18 |
| Q3 2023 | 39 | $2,785,052,000 | +$438,020,681 | -$377,680,238 | +$60,340,443 | UHS, THC, ZBH, VTRS, SNY | 13F-HR | 14 Nov 2023, 08:56 |
| Q2 2023 | 38 | $3,070,980,000 | +$270,519,447 | -$356,753,059 | -$86,233,612 | UHS, THC, VTRS, SNY, WBA | 13F-HR | 14 Aug 2023, 09:26 |
| Q1 2023 | 40 | $2,930,852,000 | +$386,554,823 | -$480,917,833 | -$94,363,010 | SNY, UHS, THC, WBA, VTRS | 13F-HR | 15 May 2023, 09:06 |
| Q4 2022 | 38 | $2,859,998,000 | +$425,061,586 | -$775,195,467 | -$350,133,881 | SNY, UHS, VTRS, THC, WBA | 13F-HR | 14 Feb 2023, 09:01 |
| Q3 2022 | 42 | $2,989,107,000 | +$983,271,417 | -$247,129,351 | +$736,142,066 | SNY, VTRS, UHS, SRPT, THC | 13F-HR | 14 Nov 2022, 09:37 |
| Q2 2022 | 40 | $2,304,904,000 | +$475,521,796 | -$653,017,821 | -$177,496,025 | VTRS, SNY, ZBH, SRPT, BMRN | 13F-HR | 15 Aug 2022, 08:55 |
| Q1 2022 | 37 | $2,764,515,000 | +$768,170,530 | -$486,594,500 | +$281,576,030 | VTRS, UHS, SNY, ZBH, GILD | 13F-HR | 16 May 2022, 08:39 |
| Q4 2021 | 36 | $2,593,820,000 | +$586,866,278 | -$596,912,085 | -$10,045,807 | VTRS, UHS, MRK, SNY, WBA | 13F-HR | 14 Feb 2022, 09:33 |
| Q3 2021 | 34 | $2,690,694,000 | +$614,985,565 | -$375,409,607 | +$239,575,958 | UHS, WBA, THC, VTRS, SNY | 13F-HR | 15 Nov 2021, 09:03 |
| Q2 2021 | 30 | $2,545,512,000 | +$540,861,491 | -$678,447,075 | -$137,585,584 | THC, WBA, VTRS, HCA, BKD | 13F-HR | 16 Aug 2021, 08:52 |
| Q1 2021 | 31 | $2,517,863,000 | +$594,764,727 | -$656,469,048 | -$61,704,321 | CHNG, WBA, UHS, VTRS, THC | 13F-HR | 17 May 2021, 08:49 |
| Q4 2020 | 28 | $2,432,483,000 | +$681,923,229 | -$481,255,287 | +$200,667,942 | CHNG, VTRS, UHS, ALXN, HCA | 13F-HR | 16 Feb 2021, 08:33 |
| Q3 2020 | 35 | $1,895,842,000 | +$447,888,597 | -$286,999,572 | +$160,889,025 | CHNG, MYL, ALXN, PRGO, UHS | 13F-HR/A | 16 Nov 2020, 16:51 |
| Q3 2020 | 35 | $1,895,277,000 | +$447,323,597 | -$286,999,572 | +$160,324,025 | CHNG, MYL, ALXN, PRGO, UHS | 13F-HR | 16 Nov 2020, 08:39 |
| Q2 2020 | 30 | $1,747,847,000 | +$438,580,414 | -$597,929,612 | -$159,349,198 | CHNG, MYL, ALXN, ALKS, PRGO | 13F-HR | 14 Aug 2020, 08:25 |
| Q1 2020 | 29 | $1,674,643,000 | +$775,265,166 | -$668,967,157 | +$106,298,009 | ALXN, CHNG, MYL, GSK, UHS | 13F-HR | 15 May 2020, 08:52 |
| Q4 2019 | 28 | $1,932,959,000 | +$280,846,111 | -$460,540,326 | -$179,694,215 | AGN, MYL, BIIB, GILD, THC | 13F-HR | 14 Feb 2020, 09:22 |
| Q3 2019 | 32 | $1,758,169,000 | +$453,124,857 | -$350,006,000 | +$103,118,857 | AGN, MYL, PRGO, BKD, DVA | 13F-HR | 14 Nov 2019, 09:15 |
| Q2 2019 | 28 | $1,711,598,000 | +$433,076,669 | -$368,745,964 | +$64,330,705 | AGN, MYL, DVA, PRGO, BKD | 13F-HR | 14 Aug 2019, 09:16 |
| Q1 2019 | 27 | $1,724,502,000 | +$431,602,460 | -$809,301,126 | -$377,698,666 | AGN, MYL, PRGO, GBT, BIIB | 13F-HR | 15 May 2019, 09:45 |
| Q4 2018 | 32 | $1,850,246,000 | +$623,265,257 | -$249,694,000 | +$373,571,257 | TSRO, MYL, AGN, UHS, MCK | 13F-HR | 14 Feb 2019, 10:17 |
| Q3 2018 | 25 | $1,755,379,000 | +$259,019,409 | -$719,304,922 | -$460,285,513 | AGN, HCA, MYL, TSRO, UHS | 13F-HR | 14 Nov 2018, 09:55 |
| Q2 2018 | 30 | $2,137,678,000 | +$417,712,456 | -$395,064,408 | +$22,648,048 | AGN, HCA, BIIB, GHDX, TSRO | 13F-HR | 14 Aug 2018, 09:23 |
| Q1 2018 | 32 | $2,036,804,000 | +$765,071,443 | -$472,755,177 | +$292,316,266 | SHPG, NKTR, AGN, BIIB, HCA | 13F-HR | 15 May 2018, 08:48 |
| Q4 2017 | 31 | $1,533,430,000 | +$537,093,057 | -$387,148,293 | +$149,944,764 | NKTR, HCA, MYL, AGN, UHS | 13F-HR | 14 Feb 2018, 10:22 |
| Q3 2017 | 22 | $1,201,035,000 | +$359,542,788 | -$806,842,839 | -$447,300,051 | NKTR, THC, MYL, PRGO, GHDX | 13F-HR | 14 Nov 2017, 11:21 |
| Q2 2017 | 31 | $1,637,441,000 | +$271,890,640 | -$468,190,457 | -$196,299,817 | TEVA, MYL, GILD, NKTR, AGN | 13F-HR | 14 Aug 2017, 11:18 |
| Q1 2017 | 30 | $1,690,383,000 | +$216,915,818 | -$375,615,537 | -$158,699,719 | TEVA, MYL, GILD, NKTR, AGN | 13F-HR | 15 May 2017, 11:17 |
| Q4 2016 | 34 | $1,728,958,000 | +$557,876,923 | -$309,354,604 | +$248,522,319 | TEVA, MYL, AGN, GILD, PRGO | Restatement | 16 Mar 2017, 09:19 |
| Q3 2016 | 33 | $1,616,779,000 | +$291,989,787 | -$498,373,548 | -$206,383,761 | TEVA, MYL, PRGO, GILD, ENDPQ | 13F-HR | 14 Nov 2016, 11:20 |
| Q2 2016 | 44 | $1,719,699,000 | +$615,848,664 | -$514,180,465 | +$101,668,199 | TEVA, MYL, ENDPQ, CSII, MDCO | 13F-HR | 12 Aug 2016, 15:43 |
| Q1 2016 | 45 | $1,608,195,000 | +$591,694,901 | -$213,395,000 | +$378,299,901 | TEVA, MYL, MDCO, BKD, NUVA | 13F-HR | 13 May 2016, 16:00 |
| Q4 2015 | 40 | $1,355,685,000 | +$387,180,736 | -$317,613,961 | +$69,566,775 | TEVA, GHDX, MDCO, LIVN, AZN | 13F-HR | 12 Feb 2016, 08:17 |
| Q3 2015 | 43 | $1,167,351,000 | +$285,497,480 | -$173,301,642 | +$112,195,838 | TEVA, MDCO, AZN, CYBX, MYL | 13F-HR | 13 Nov 2015, 10:37 |
| Q2 2015 | 39 | $1,242,600,000 | +$384,309,605 | -$286,990,920 | +$97,318,685 | TEVA, AZN, MASI, MDCO, ESRX | 13F-HR | 14 Aug 2015, 10:07 |
| Q1 2015 | 36 | $1,183,566,000 | +$281,607,926 | -$388,429,725 | -$106,821,799 | TEVA, MASI, MDCO, GHDX, ESRX | 13F-HR | 15 May 2015, 11:09 |
| Q4 2014 | 38 | $1,195,660,000 | +$334,135,594 | -$272,097,853 | +$62,037,741 | TEVA, MASI, GSK, GHDX, CNMD | Restatement | 13 May 2015, 11:50 |
| Q3 2014 | 35 | $991,266,000 | +$343,206,741 | -$497,997,564 | -$154,790,823 | TEVA, MYL, MASI, GHDX, GSK | 13F-HR | 14 Nov 2014, 10:32 |
| Q2 2014 | 39 | $1,206,389,000 | +$334,540,896 | -$217,592,447 | +$116,948,449 | TEVA, V107SC, DGX, CYH, CNMD | 13F-HR | 14 Aug 2014, 10:03 |
| Q1 2014 | 38 | $1,042,272,000 | +$316,058,647 | -$369,544,311 | -$53,485,664 | TEVA, V107SC, THC, DGX, CNMD | 13F-HR | 15 May 2014, 10:28 |
| Q4 2013 | 35 | $1,043,531,000 | $0 | $0 | $0 | TEVA, MYL, V107SC, HCA, CNMD | 13F-HR | 14 Feb 2014, 07:55 |